Eli Lilly and Company:企業の戦略・SWOT・財務分析

【英語タイトル】Eli Lilly and Company - Strategy, SWOT and Corporate Finance Report

MarketLineが出版した調査資料(MLINE7092310)・商品コード:MLINE7092310
・発行会社(調査会社):MarketLine
・発行日:2017年1月31日
・ページ数:58
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD175 ⇒換算¥19,775見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD350 ⇒換算¥39,550見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD525 ⇒換算¥59,325見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

SummaryEli Lilly and Company – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Findings
- Detailed information on Eli Lilly and Company required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Eli Lilly and Company in the form of a SWOT analysis
- An in-depth view of the business model of Eli Lilly and Company including a breakdown and examination of key business segments
- Intelligence on Eli Lilly and Company’s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Eli Lilly and Company, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons To Buy
- Gain understanding of Eli Lilly and Company and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Eli Lilly and Company as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers’ businesses better.
- Stay up to date on Eli Lilly and Company’s business structure, strategy and prospects.

Key Highlights
Eli Lilly and Company (Eli Lilly or ‘the company’) is engaged in developing, manufacturing, and marketing pharmaceutical products and animal health products. The company operates in the US, Japan, Europe, and other countries. It is headquartered in Indianapolis, Indiana.

【レポートの目次】

Company Snapshot
Eli Lilly and Company: Company Overview
Eli Lilly and Company: Overview and Key Facts
Eli Lilly and Company: Overview
Eli Lilly and Company: Key Facts
Eli Lilly and Company: Key Employees
Eli Lilly and Company: Key Employee Biographies
Eli Lilly and Company: Major Products and Services
Eli Lilly and Company: Company History
Eli Lilly and Company: Management Statement
Eli Lilly and Company: Locations and Subsidiaries
Eli Lilly and Company: Key Competitors
Eli Lilly and Company: Company Analysis
Eli Lilly and Company: Business Description
Eli Lilly and Company: SWOT Analysis
Eli Lilly and Company: SWOT Overview
Eli Lilly and Company: Strengths
Eli Lilly and Company: Weaknesses
Eli Lilly and Company: Opportunities
Eli Lilly and Company: Threats
Eli Lilly and Company: Corporate Financial Deals Activity
Eli Lilly and Company: Financial Deals Overview
Eli Lilly and Company: Targets and Partners
Eli Lilly and Company: Top Deals 2013 – 2017YTD*
Eli Lilly and Company: Advisors
Eli Lilly and Company: Top Financial Advisors
Eli Lilly and Company: Mergers and Acquisitions
Eli Lilly and Company: Corporate Venturing
Eli Lilly and Company: Partnership
Eli Lilly and Company: Divestments
Eli Lilly and Company: Recent Developments
Eli Lilly and Company: News and Events Summary
Eli Lilly and Company: Business Expansion
Eli Lilly and Company: Contracts
Eli Lilly and Company: Financial Performance
Eli Lilly and Company: Regulatory and Legal Events
Eli Lilly and Company: Research and Development
Eli Lilly and Company: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions
About Datamonitor

Table 1: Eli Lilly and Company: Key Facts
Table 2: Eli Lilly and Company: Key Employees
Table 4: Eli Lilly and Company: Key Competitors
Table 5: Eli Lilly and Company: Deal Activity by Deal Type - Volume (TTM*)
Table 6: Eli Lilly and Company: Deal Activity by Deal Type - Volume (2013 - YTD*2017)
Table 7: Eli Lilly and Company: MandA Average Deal Size - Value (US$m)
Table 8: Eli Lilly and Company: Targets and Partners
Table 9: Eli Lilly and Company: Top Deals 2013 - 2017YTD*
Table 10: Eli Lilly and Company: Financial Advisor Ranking by Value (US$m)
Table 11: Eli Lilly and Company: MandA Volume and Value Trend (2013 - YTD*2017)
Table 12: Eli Lilly and Company: MandA Activity by Geography (2013 - YTD*2017)
Table 13: Eli Lilly and Company: Corporate Venturing Volume and Value Trend (2013 - YTD*2017)
Table 14: Eli Lilly and Company: Corporate Venturing by Geography (2013 - YTD*2017)
Table 15: Eli Lilly and Company: Partnership Volume and Value Trend (2013 - YTD*2017)
Table 16: Eli Lilly and Company: Partnership Trend by Deal Type (2013 - YTD*2017)
Table 17: Eli Lilly and Company: Divestments Volume and Value Trend (2013 - YTD*2017)
Table 18: Eli Lilly and Company: Divestments by Geography (2013 - YTD*2017)
Table 19: Eli Lilly and Company: News and Events Summary
Table 20: Eli Lilly and Company: Business Expansion
Table 21: Eli Lilly and Company: Contracts
Table 22: Eli Lilly and Company: Financial Performance
Table 23: Eli Lilly and Company: Regulatory and Legal Events
Table 24: Eli Lilly and Company: Research and Development
Table 25: Eli Lilly and Company: Strategy and Operations

Figure 1: Eli Lilly and Company: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: Eli Lilly and Company: Deal Activity by Deal Type - Volume (2013 - YTD*2017)
Figure 3: Eli Lilly and Company: MandA Average Deal Size - Value (US$m)
Figure 4: Eli Lilly and Company: MandA Volume and Value Trend (2013 - YTD*2017)
Figure 5: Eli Lilly and Company: MandA Activity by Geography (2013 - YTD*2017)
Figure 6: Eli Lilly and Company: Corporate Venturing Volume and Value Trend (2013 - YTD*2017)
Figure 7: Eli Lilly and Company: Corporate Venturing by Geography (2013 - YTD*2017)
Figure 8: Eli Lilly and Company: Partnership Volume and Value Trend (2013 - YTD*2017)
Figure 9: Eli Lilly and Company: Partnership Trend by Deal Type (2013 - YTD*2017)
Figure 10: Eli Lilly and Company: Divestments Volume and Value Trend (2013 - YTD*2017)
Figure 11: Eli Lilly and Company: Divestments by Geography (2013 - YTD*2017)

★調査レポート[Eli Lilly and Company:企業の戦略・SWOT・財務分析] (コード:MLINE7092310)販売に関する免責事項を必ずご確認ください。
★調査レポート[Eli Lilly and Company:企業の戦略・SWOT・財務分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆